| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JCRC.2010.08.004 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0883944110002200?httpAccept=text/xml |
| https://api.elsevier.com/content/article/PII:S0883944110002200?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 20889286 |
| P2093 | author name string | Lobelia Samavati | |
| Gustavo Cumbo-Nacheli | |||
| Jorge A. Guzman | |||
| P2860 | cites work | Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213383 |
| Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) | Q28284893 | ||
| Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial | Q33919099 | ||
| Bad medicine: low-dose dopamine in the ICU. | Q34189377 | ||
| Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial | Q34343613 | ||
| Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery | Q34561015 | ||
| Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. | Q34999668 | ||
| Pharmacologic issues in the critically ill. | Q35622678 | ||
| Pharmacokinetic changes in critical illness | Q36469758 | ||
| Measuring the anticoagulant effect of low molecular weight heparins in the critically ill | Q36552253 | ||
| Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors | Q36748915 | ||
| Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial | Q38408470 | ||
| Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients | Q39883604 | ||
| Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors | Q43473293 | ||
| Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery | Q43856529 | ||
| Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin | Q43942831 | ||
| Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? | Q44456723 | ||
| Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. | Q47190616 | ||
| Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease | Q74790171 | ||
| Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes | Q81038771 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bioavailability | Q461809 |
| critical illness | Q65807521 | ||
| P304 | page(s) | 342-346 | |
| P577 | publication date | 2010-10-02 | |
| P1433 | published in | Journal of Critical Care | Q15749406 |
| P1476 | title | Bioavailability of fondaparinux to critically ill patients | |
| P478 | volume | 26 |
| Q39911405 | Fludrocortisone for heparin-induced hyperkalemia |
| Q33410578 | Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux |
| Q34140686 | Reducing medication errors in critical care: a multimodal approach. |
| Q34052232 | Role of factor xa inhibitors in cancer-associated thrombosis: any new data? |
Search more.